Zemlan, Ph.D., Chief Executive Officer, has over 20 years
of experience in clinical research for Fortune 500 drug companies including Novartis, Pfizer and Eli Lilly. Frank holds several
biotech patents and has direct experience in drug licensing and intellectual property management. He has started two successful
biotech companies, Mind Probes - a diagnostic company that licensed its platform technology to Biosite (Nasdaq: BSTE) and
Phase 2 Discovery that out-licensed its proprietary Phase 3-ready insomnia drug. Frank received his graduate training
at the University of Pennsylvania School of Medicine and has served on the faculty of Princeton University, Rockefeller University
in New York City and the University of Cincinnati College of Medicine where he attained the rank of tenured University Professor.
Frank serves on several national grant review committees including the Center for Scientific Review at the National Institutes
of Health and is a reviewer for many journals in the fields of psychiatry and neuroscience. He is the author of over 200 scientific
publications and book chapters.
Prasad Gabbita, Ph.D., Vice President of Research and Development, has lead the preclinical drug discovery, development
and biomarker assay programs at P2D Bioscience and its predecessor companies for the past ten years. He brings 15 years
of research experience and knowledge in neuroscience, toxicology, synthetic organic chemistry and drug formulation.
Prasad received his doctoral and post-doctoral training at the University of Kentucky College of Medicine and Sanders Brown
Center on Aging in Lexington. He has been the recipient of nearly $ 2 MM in research funding for drug and diagnostic
development from several agencies including the Michael J. Fox Foundation, the Alzheimer’s Drug Discovery Foundation
and the National Institutes of Health. Prasad has authored about 20 peer-reviewed scientific publications and book chapters.